Tags

Type your tag names separated by a space and hit enter

The Relationship Between Anticholinergic Exposure and Falls, Fractures, and Mortality in Patients with Overactive Bladder.
Drugs Aging. 2019 10; 36(10):957-967.DA

Abstract

BACKGROUND

Understanding risk factors associated with falls is important for optimizing care and quality of life for older patients.

OBJECTIVE

Our objective was to determine the relationship between anticholinergic exposure and falls, fractures, and all-cause mortality.

METHODS

An observational retrospective cohort study was conducted using administrative claims data from 1 January 2007 to 30 September 2015. Individuals aged 65-89 years newly diagnosed or treated for overactive bladder (OAB) were identified. Index date was the first OAB diagnosis or OAB medication prescription claim. Follow-up began on the index date and continued until death, disenrollment, or end of study period. The Anticholinergic Cognitive Burden (ACB) scale was used to define and quantify daily anticholinergic exposure and intensity. The primary study outcome was a combined endpoint of falls or fractures. All-cause mortality was a secondary endpoint.

RESULTS

There were 113,311 patients with mean age of 74.8 ± standard deviation (SD) 6.2 years included. Current anticholinergic exposure was associated with a 1.28-fold increased hazard of a fall/fracture (95% confidence interval [CI] 1.23-1.32) compared with unexposed person-time, and past exposure was associated with a 1.14-fold increased hazard of a fall/fracture (95% CI 1.12-1.17). Compared with unexposed person-time, low-, moderate-, and high-intensity anticholinergic exposure was associated with a 1.04-fold (95% CI 1.00-1.07), 1.13-fold (95% CI 1.09-1.17), and 1.31-fold (95% CI 1.26-1.36) increased hazard of falls/fractures, respectively. A similar pattern was observed for all-cause mortality.

CONCLUSIONS

Anticholinergic exposure is associated with an increased risk of falls or fractures in older patients and is an important consideration when evaluating treatment options for such patients with OAB.

Authors+Show Affiliations

Humana Healthcare Research, Inc., Louisville, KY, USA. bsuehs6@humana.com.Humana Healthcare Research, Inc., Louisville, KY, USA.Humana Healthcare Research, Inc., Louisville, KY, USA.Astellas Pharma Global Development, Inc., Northbrook, IL, USA.Humana Inc., Louisville, KY, USA.

Pub Type(s)

Journal Article
Observational Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

31359329

Citation

Suehs, Brandon T., et al. "The Relationship Between Anticholinergic Exposure and Falls, Fractures, and Mortality in Patients With Overactive Bladder." Drugs & Aging, vol. 36, no. 10, 2019, pp. 957-967.
Suehs BT, Caplan EO, Hayden J, et al. The Relationship Between Anticholinergic Exposure and Falls, Fractures, and Mortality in Patients with Overactive Bladder. Drugs Aging. 2019;36(10):957-967.
Suehs, B. T., Caplan, E. O., Hayden, J., Ng, D. B., & Gaddy, R. R. (2019). The Relationship Between Anticholinergic Exposure and Falls, Fractures, and Mortality in Patients with Overactive Bladder. Drugs & Aging, 36(10), 957-967. https://doi.org/10.1007/s40266-019-00694-5
Suehs BT, et al. The Relationship Between Anticholinergic Exposure and Falls, Fractures, and Mortality in Patients With Overactive Bladder. Drugs Aging. 2019;36(10):957-967. PubMed PMID: 31359329.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The Relationship Between Anticholinergic Exposure and Falls, Fractures, and Mortality in Patients with Overactive Bladder. AU - Suehs,Brandon T, AU - Caplan,Eleanor O, AU - Hayden,Jennifer, AU - Ng,Daniel B, AU - Gaddy,Rainelle R, PY - 2019/7/31/pubmed PY - 2020/1/29/medline PY - 2019/7/31/entrez SP - 957 EP - 967 JF - Drugs & aging JO - Drugs Aging VL - 36 IS - 10 N2 - BACKGROUND: Understanding risk factors associated with falls is important for optimizing care and quality of life for older patients. OBJECTIVE: Our objective was to determine the relationship between anticholinergic exposure and falls, fractures, and all-cause mortality. METHODS: An observational retrospective cohort study was conducted using administrative claims data from 1 January 2007 to 30 September 2015. Individuals aged 65-89 years newly diagnosed or treated for overactive bladder (OAB) were identified. Index date was the first OAB diagnosis or OAB medication prescription claim. Follow-up began on the index date and continued until death, disenrollment, or end of study period. The Anticholinergic Cognitive Burden (ACB) scale was used to define and quantify daily anticholinergic exposure and intensity. The primary study outcome was a combined endpoint of falls or fractures. All-cause mortality was a secondary endpoint. RESULTS: There were 113,311 patients with mean age of 74.8 ± standard deviation (SD) 6.2 years included. Current anticholinergic exposure was associated with a 1.28-fold increased hazard of a fall/fracture (95% confidence interval [CI] 1.23-1.32) compared with unexposed person-time, and past exposure was associated with a 1.14-fold increased hazard of a fall/fracture (95% CI 1.12-1.17). Compared with unexposed person-time, low-, moderate-, and high-intensity anticholinergic exposure was associated with a 1.04-fold (95% CI 1.00-1.07), 1.13-fold (95% CI 1.09-1.17), and 1.31-fold (95% CI 1.26-1.36) increased hazard of falls/fractures, respectively. A similar pattern was observed for all-cause mortality. CONCLUSIONS: Anticholinergic exposure is associated with an increased risk of falls or fractures in older patients and is an important consideration when evaluating treatment options for such patients with OAB. SN - 1179-1969 UR - https://www.unboundmedicine.com/medline/citation/31359329/The_Relationship_Between_Anticholinergic_Exposure_and_Falls_Fractures_and_Mortality_in_Patients_with_Overactive_Bladder_ L2 - https://dx.doi.org/10.1007/s40266-019-00694-5 DB - PRIME DP - Unbound Medicine ER -